Browsing Tag
ECLIPSE 1
1 post
Vir Biotechnology just finished its HDV Phase 3 enrolment early—here’s why investors are watching
Vir Biotechnology completes ECLIPSE 1 trial enrolment early and secures a funding runway into mid-2027. See what this means for its hepatitis delta ambitions.